222036-66-0

Basic information

• Product Name: 1H-Isoindol-1-one,5-amino-2,3-dihydro-(9CI)
• Synonyms: 1H-Isoindol-1-one,5-amino-2,3-dihydro-(9CI);5-amino-2,3-dihydro-1H-Isoindol-1-one;5-aminoisoindolin-1-one;1H-Isoindol-1-one, 5-amino-2,3-dihydro;5-aMino-2,3-dihydro- Isoindol-1-one;5-aMinoisoindoline-1-one
• CAS NO: 222036-66-0
• Molecular Formula: C₈H₈N₂O
• Molecular Weight: 148.17
• EINECS: 1592732-453-0
• Product Categories: AMINEPRIMARY;Quinolines
• Mol File: 222036-66-0.mol

Chemical Properties

• Melting Point: 197-199 °C(Solv: ethyl acetate (141-78-6))
• Boiling Point: 520.034 °C at 760 mmHg
• Flash Point: 268.307 °C
• Appearance: /
• Density: 1.307g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.654
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 15.12±0.20(Predicted)
• CAS DataBase Reference: 1H-Isoindol-1-one,5-amino-2,3-dihydro-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Isoindol-1-one,5-amino-2,3-dihydro-(9CI)(222036-66-0)
• EPA Substance Registry System: 1H-Isoindol-1-one,5-amino-2,3-dihydro-(9CI)(222036-66-0)

Safety Data

• Hazardous Substances Data: 222036-66-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1H-Isoindol-1-one,5-amino-2,3-dihydro-(9CI) is used as a key intermediate in the synthesis of novel and potent glycoprotein IIb-IIIa (GP IIb-IIIa) receptor antagonists. These antagonists are crucial in the development of therapeutic agents for various medical conditions, particularly those involving blood clotting and cardiovascular diseases. The unique structure of 5-Aminoisoindolin-1-one allows for the design of highly specific and effective GP IIb-IIIa receptor antagonists, which can potentially improve patient outcomes and reduce the risk of complications associated with existing treatments.

InChI:InChI=1/C8H8N2O/c9-6-1-2-7-5(3-6)4-10-8(7)11/h1-3H,4,9H2,(H,10,11)

Upstream product

• 2518-24-3 3-aminophthalimide 
• 1113057-04-7 ethyl 4-amino-2-aminomethyl-benzoate monohydrochloride 
• 62621-09-4 methyl 2-methyl-4-nitrobenzoate 
• 552330-86-6 5-bromoisoindolin-1-one 
• 1357104-48-3 C₁₈H₁₅F₃N₂O₃ 
• 1357104-53-0 C₁₀H₇F₃N₂O₂ 
• 133446-99-8 2-bromomethyl-4-nitro-benzoic acid methyl ester 
• 1975-51-5 2-methyl-4-nitrobenzoic acid 
• 110568-64-4 2,3-Dihydro-6-nitro-1H-isoindol-1-on 

Downstream Products

• 1571073-74-9 1-(4-((2-((1-oxoisoindolin-5-yl)amino)pyrimidin-4-yl)oxy)naphthalen-1-yl)-3-(1-(p-tolyl)-3-(trimethylsilyl)-1H-pyrazol-5-yl)urea 
• 1401461-58-2 1-(7-(3,4-dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)-N-(1-oxoisoindolin-5-yl)piperidine-3-carboxamide 

Relevant articles and documents

A kind of diaryl hydanto?n derivatives, its preparation method, pharmaceutical composition and application

Provided are a compound as represented by formula I, or pharmaceutically acceptable salt, solvate, precursor drug, stereoisomer, tautomer, polymorph or metabolite thereof, pharmaceutical composition containing same, and uses thereof in the preparation of drugs for treating androgen receptor related diseases.

BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS

Disclosed are promoieties of the following formula which can be used to form prodrugs of nitrogen-containing or hydroxyl-containing drug or a pharmaceutically active agent: (I) and pharmaceutical compositions comprising the prodrugs.

Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS

The invention relates to a novel class of 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as a FAK and/or Pyk2 inhibitor, to a process for their preparation, and to a composition thereof, as well as to use of the compounds for the inhibiting FAK and/or Pyk2 and method for the treatment of a FAK and/ or Pyk2 mediated disorder or disease.

Design, synthesis, and structure-activity relationship studies of conformationally restricted mutilin 14-carbamates

We report herein the design, synthesis, and structure-activity relationship studies of conformationally restricted mutilin 14-carbamates based on the structure of SB-222734. The antibacterial activities of these newly synthesized compounds were also evaluated and compared with linezolid and retapamulin. Results showed that most of the target compounds exhibit good potency in inhibiting the growth of Gram-positive bacteria including Methicillin- susceptible Staphylococcus aureus MSSA (MIC: 0.0625-2 μg/mL), Methicillin-resistant S. aureus MRSA (MIC: 0.0625-2 μg/mL), Methicillin-susceptible Staphylococcus epidermidis MSSE (MIC: 0.0625-2 μg/mL), Methicillin-resistant S. epidermidis MRSE (MIC: 0.0625-2 μg/mL), and Streptococcus pneumonia (MIC: 0.0625-4 μg/mL). In particular, three remarkable compounds of this series (12l, 12m, and 21l) exhibited comparable in vitro antibacterial profiles to that of retapamulin.

SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

Substituted cyclopropyl compounds of the formula I: are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.

4-PHENOXY-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE AND N-ARYL-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES

The invention relates to 4,6-disubstituted-1H-pyrazolo[3,4-d]pyrimidin-4-amine compounds, including 4-phenoxy-6-aryl-1H-pyrazolo[3,4-d]pyrimidine and N-aryl-6-aryl-1H-pyrazolo[3,4-d]pyrimidin-4-amine compounds of the Formula I: or a pharmaceutically accep

Guanidino substituted isoindolones as novel glycoprotein IIb-IIIa receptor antagonists

Design and synthesis of a novel potent glycoprotein IIb-IIIa (GP IIb-IIIa) receptor antagonist based on isoindolone skeleton has been described. This scaffold has been derived from earlier reported pseudopeptides. Synthesis by a novel route has been achieved. Few molecules show very potent in vitro activity. Further identification of probable additional hydrogen bond donor site has been described.

ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE INHIBITING COMPOUNDS

Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mekl, PDK-1, GSK3?, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2